1.
Pädiatrie
; 35(2):62-62, 2023.
Article
in German
| EuropePMC | ID: covidwho-2294817
2.
MMW Fortschr Med
; 165(8): 57, 2023 04.
Article
in German
| MEDLINE | ID: covidwho-2294816
3.
MMW Fortschr Med
; 165(1): 71, 2023 01.
Article
in German
| MEDLINE | ID: covidwho-2229848
4.
MMW Fortschr Med
; 165(1): 70, 2023 01.
Article
in German
| MEDLINE | ID: covidwho-2229847
Subject(s)
COVID-19 Vaccines , COVID-19 , Child , Humans , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects
5.
Pneumo news
; 13(6):12-13, 2021.
Article
in German
| EuropePMC | ID: covidwho-2207561
6.
MMW Fortschr Med
; 164(21-22): 74, 2022 12.
Article
in German
| MEDLINE | ID: covidwho-2158218
7.
MMW Fortschr Med
; 164(20): 74, 2022 11.
Article
in German
| MEDLINE | ID: covidwho-2116755
8.
MMW Fortschr Med
; 164(19): 73, 2022 11.
Article
in German
| MEDLINE | ID: covidwho-2094823
9.
MMW Fortschr Med
; 164(18): 72, 2022 10.
Article
in German
| MEDLINE | ID: covidwho-2075709
10.
MMW Fortschr Med
; 164(16): 63, 2022 09.
Article
in German
| MEDLINE | ID: covidwho-2075707
Subject(s)
COVID-19 , Practice Guidelines as Topic , COVID-19/complications , Humans , Post-Acute COVID-19 Syndrome
11.
CME (Berlin, Germany)
; 19(10):56-58, 2022.
Article
in German
| EuropePMC | ID: covidwho-2073033
12.
Orthopädie und Unfallchirurgie
; 12(1):8-9, 2022.
Article
in German
| EuropePMC | ID: covidwho-1678057
ABSTRACT
Häufiger Post-COVID-Diagnose bei Volkskrankheiten
13.
MMW Fortschr Med
; 164(17): 70, 2022 10.
Article
in German
| MEDLINE | ID: covidwho-2048624
14.
MMW Fortschr Med
; 164(16): 66, 2022 09.
Article
in German
| MEDLINE | ID: covidwho-2035444
Subject(s)
COVID-19 , Influenza Vaccines , Influenza, Human , COVID-19 Vaccines , Humans , Influenza, Human/prevention & control
15.
HNO-Nachrichten
; 52(4):53-53, 2022.
Article
in German
| EuropePMC | ID: covidwho-2033933
16.
MMW Fortschr Med
; 164(15): 63, 2022 09.
Article
in German
| MEDLINE | ID: covidwho-2014582
17.
Gastro-News
; 8(6):64-67, 2021.
Article
in German
| PMC | ID: covidwho-1579018
ABSTRACT
The Galenus Prize 2021 in the category "Primary Care" went to Comirnaty® from BioNTech and Pfizer. This is the first vaccine based on mRNA technology to be approved. The vaccine, which was developed in record time, contains messenger RNA packaged in lipid nanoparticles that codes for the SARS-CoV-2 spike protein. The protein is produced and distributed in the body cells according to this blueprint. This induces an immune response that is highly effective in protecting against COVID-19.
18.
MMW Fortschr Med
; 164(14): 70, 2022 08.
Article
in German
| MEDLINE | ID: covidwho-1982394
19.
MMW Fortschr Med
; 163(11): 11, 2021 Jun.
Article
in German
| MEDLINE | ID: covidwho-1271540
20.
MMW Fortschr Med
; 164(7): 63, 2022 04.
Article
in German
| MEDLINE | ID: covidwho-1959185